Clinical Trial Update: A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma [Phase 2]

View source ↗

Summary

A Phase II clinical trial evaluates Axicabtagene Ciloleucel (axi-cel), a CD19 CAR-T therapy, in combination with radiotherapy for relapsed/refractory follicular…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Yescarta (axicabtagene ciloleucel)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Follicular Lymphoma | Phase 2 | Status: RECRUITING